Mythic Therapeutics Presents Compelling Efficacy Data from its Phase 1 KisMET-01 Study Supporting Best-in-Class Potential of Novel cMET- ADC, MYTX-011, in Non-Small Cell Lung Cancer at the ...

The cell-to-module efficiency gap observed in a-Si/c-Si heterojunction solar cells is a key challenge to the broad adoption of this technology. To systematically address this issue, we describe an end ...

ZL-1310, a DLL3-targeted antibody drug conjugate (ADC) with a topoisomerase 1 inhibitor payload and cleavable linker, demonstrated promising preliminary results in pts with relapsed/refractory (r/r) ...

More than 13 years after its initial FDA approval, Pfizer’s blood cancer drug Adcetris has nabbed another regulatory green light to treat large B-cell lymphoma (LBCL).

The ADC module helped to characterize payload molecules with exceptional potency, exhibiting GI50 values from picomolar to 10 nM (nanomolar) ranges. These payload molecules can be further optimized by ...

Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC) ...

ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell ...

EliTe Solar has announced plans to build an 8GW cell and module manufacturing facility in the Suez Canal Economic Zone (SCZONE) in Egypt.

Merck & Co.’s long-running effort to land a punch on small cell lung cancer (SCLC) has racked up a small victory. The drugmaker’s Daiichi Sankyo-partnered antibody-drug conjugate (ADC ...

In the driver of the HX711 load cell, the HX711_ADC library is called, and the calibration factor for the load cell is set to 208 by weight calibration. The driver of HX711 has the function of ...

Dose escalation and expansion results from the phase I study of F0024, a trophoblast cell-surface antigen 2 (TROP2) antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors.